HC Wainwright & Co. Reiterates Buy on Ultragenyx Pharmaceutical, Maintains $82 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Ed Arce has reiterated a 'Buy' rating on Ultragenyx Pharmaceutical (NASDAQ:RARE) and maintained a price target of $82.
August 01, 2023 | 10:21 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ultragenyx Pharmaceutical's stock rating has been reiterated as 'Buy' by HC Wainwright & Co. with a maintained price target of $82.
The reiteration of a 'Buy' rating by a reputable analyst like Ed Arce from HC Wainwright & Co. is a positive signal for Ultragenyx Pharmaceutical. The maintained price target of $82 also indicates a potential upside for the stock, which could lead to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100